UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
(Mark One)
| x | Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the quarterly period ended March 31, 2004
| ¨ | Transition report under Section 13 or 15(d) of the Exchange Act |
Commission file number: 33-55254-36
E Med Future, Inc.
(Exact name of small business issuer as specified in its charter)
| Nevada | 87-0485314 | |
| (State of incorporation) | (I.R.S. Employer Identification No.) |
794 Morrison Road, Suite 911, Columbus, OH 43230
(Address of principal executive offices)
| 877-855-1319 | www.NeedleZap.com | |
| (Issuer’s telephone number) | (Issuer’s website) |
Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 26,134,000 shares of common stock, $0.001 par value per share, as of May 1, 2003
Transitional Small Business Disclosure Format (check one): Yes ¨ No x
| 3 | ||||
| Item 1. |
Financial Statements | 3 | ||
| Item 2. |
Management’s Discussion and Analysis | 6 | ||
| 6 | ||||
| 7 | ||||
| 8 | ||||
| 8 | ||||
| 9 | ||||
| 9 | ||||
| 9 | ||||
| 9 | ||||
| 10 | ||||
| 10 | ||||
| 10 | ||||
| 11 | ||||
| Item 3. |
Controls and Procedures | 11 | ||
| 12 | ||||
| Item 1. |
Legal Proceedings | 12 | ||
| Item 2. |
Changes in Securities and Use of Proceeds | 12 | ||
| Item 3. |
Defaults Upon Senior Securities | 12 | ||
| Item 4. |
Submission of Matters to a Vote of Security Holders | 12 | ||
| Item 5. |
Other Information | 12 | ||
| Item 6. |
Exhibits and Reports on Form 8-K | 12 | ||
| (a) |
Exhibits | 12 | ||
| (b) |
Reports on Form 8-K | 12 | ||
| 13 | ||||
2
PART I — FINANCIAL INFORMATION
E MED FUTURE, INC.
Formerly Micro-Economics, Inc.
(A Development Stage Company)
CONSOLIDATED BALANCE SHEET (UNAUDITED)
March 31, 2004
| ASSETS |
||||
| CURRENT ASSETS |
||||
| Cash |
$ | 5,002 | ||
| Accounts receivable, net of allowance for doubtful account of $84,303 |
143,626 | |||
| Inventory |
292,322 | |||
| Prepaid expenses |
14,101 | |||
| Total Current Assets |
455,051 | |||
| EQUIPMENT, net of depreciation |
137,249 | |||
| PATENTS AND LICENSES |
||||
| Patents, net of amortization $46,470 |
337,926 | |||
| $ | 930,226 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||
| CURRENT LIABILITIES |
||||
| Notes payable to bank |
$ | 141,098 | ||
| Current portion of long-term debt |
1,519 | |||
| Accounts payable |
289,787 | |||
| Accounts payable to related party |
19,200 | |||
| Accrued expenses |
57,516 | |||
| Total Current Liabilities |
509,120 | |||
| LONG-TERM DEBT |
||||
| Notes payable to related party |
267,085 | |||
| Notes payable to finance company |
4,001 | |||
| STOCKHOLDERS’ EQUITY |
||||
| Common stock $0.001 par value, 50,000,000 shares authorized, 26,134,000 issued and outstanding at March 31, 2004 |
26,134 | |||
| Paid-in-capital |
1,499,632 | |||
| Deficit accumulated during development stage |
(1,375,746 | ) | ||
| 150,020 | ||||
| $ | 930,226 | |||
See accompanying notes to consolidated financial statements.
3
E MED FUTURE, INC.
Formerly Micro-Economics, Inc.
(A Development Stage Company)
CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED)
| Three Months Ended March 31, |
Period March 14, 1990 |
|||||||||||
| 2004 |
2003 |
|||||||||||
| NET SALES |
$ | 129,026 | $ | 50,542 | $ | 810,511 | ||||||
| COSTS AND EXPENSES- |
||||||||||||
| Cost of goods sold |
75,729 | 65,294 | 441,586 | |||||||||
| Selling, general and administrative |
170,764 | 55,278 | 969,012 | |||||||||
| Research and development |
— | — | 8,883 | |||||||||
| Stock based compensation |
— | 600,000 | 605,000 | |||||||||
| Depreciation and amortization |
7,668 | 7,051 | 82,553 | |||||||||
| Total Costs and Expenses |
254,161 | 727,623 | 2,107,034 | |||||||||
| NET OPERATING LOSS |
(125,135 | ) | (677,081 | ) | (1,296,523 | ) | ||||||
| OTHER INCOME (EXPENSE) |
||||||||||||
| Interest and other income |
— | — | 23 | |||||||||
| Interest expense |
(1,738 | ) | — | (10,051 | ) | |||||||
| Total Other Expenses |
(1,738 | ) | — | (10,028 | ) | |||||||
| NET LOSS |
$ | (126,873 | ) | $ | (677,081 | ) | $ | (1,306,551 | ) | |||
| NET LOSS PER COMMON SHARE - (Basic and diluted) |
$ | (0.01 | ) | $ | (0.56 | ) | $ | (0.46 | ) | |||
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING |
26,134,000 | 1,208,333 | 2,829,220 | |||||||||
See accompanying notes to consolidated financial statements.
4
E MED FUTURE, INC.
Formerly Micro-Economics, Inc.
(A Development Stage Company)
CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)
| Three Months Ended March 31, |
Period March 14, 1990 |
|||||||||||
| 2004 |
2003 |
2004 |
||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES |
||||||||||||
| Net loss |
$ | (126,873 | ) | $ | (677,081 | ) | $ | (1,375,746 | ) | |||
| Adjustments to reconcile net loss to net cash provided by operating activities: |
||||||||||||
| Depreciation and amortization |
7,668 | 7,051 | 82,552 | |||||||||
| Stock based compensation |
— | 600,000 | 605,000 | |||||||||
| Research and development costs |
— | — | 8,808 | |||||||||
| Start-up costs |
— | — | 19,177 | |||||||||
| Amortization of prepaid expense |
16,575 | |||||||||||
| Changes in operating assets and liabilities: |
||||||||||||
| Accounts receivable |
(44,064 | ) | (41,568 | ) | (143,626 | ) | ||||||
| Inventory |
19,946 | 9,053 | (141,309 | ) | ||||||||
| Prepaid expenses |
(74 | ) | 825 | (74 | ) | |||||||
| Accounts payable |
38,865 | 37,303 | 289,787 | |||||||||
| Accounts payable to related party |
(47,776 | ) | — | 19,200 | ||||||||
| Accrued expenses |
13,686 | 4,165 | 57,516 | |||||||||
| Net Cash Used in Operating Activities |
(138,622 | ) | (60,252 | ) | (562,140 | ) | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES |
||||||||||||
| Purchases of property and equipment |
(12,839 | ) | — | (48,227 | ) | |||||||
| Net Cash Used in Investing Activities |
(12,839 | ) | — | (48,227 | ) | |||||||
| CASH FLOWS FROM FINANCING ACTIVITIES |
||||||||||||
| Initial capitalization |
— | — | 1,666 | |||||||||
| Cash acquired in acquisition |
— | — | 200,000 | |||||||||
| Notes payable to bank |
— | 35,000 | 141,098 | |||||||||
| Notes payable to financing company |
5,520 | — | 5,520 | |||||||||
| Notes payable to related party |
(53,500 | ) | 20,000 | 267,085 | ||||||||
| Net Cash Provided by Financing Activities |
(47,980 | ) | 55,000 | 615,369 | ||||||||
| NET(DECREASE) INCREASE IN CASH |
199,441 | (5,252 | ) | 5,002 | ||||||||
| CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD |
204,443 | 13,216 | ||||||||||
| CASH AND CASH EQUIVALENTS END OF PERIOD |
$ | 5,002 | $ | 7,964 | $ | 5,002 | ||||||
| Supplemental Schedule of Non-Cash Operating and Financing Activities |
||||||||||||
| NeedleZap Partnership Contribution of Assets to Company |
||||||||||||
| Inventory |
— | — | $ | 151,015 | ||||||||
| Equipment |
— | — | 133,912 | |||||||||
| Patent |
— | — | 187,089 | |||||||||
| Issuance of 34,000 shares at $0.90 per share for Strategic Alliance Agreement |
— | — | 30,600 | |||||||||
| Issuance of 1,250,000 shares valued at $0.3108 per share to acquire MSTI and allocation of purchase price to license |
— | — | 188,500 | |||||||||
| Interest paid |
$ | 1,738 | — | 10,051 | ||||||||
See accompanying notes to consolidated financial statements.
5
E MED FUTURE, INC.
Formerly Micro-Economics, Inc.
(A Development Stage Company)
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
NOTE 1 BASIS OF PRESENTATION
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary in order to make the financial statements not misleading have been included. Results for the three months ended March 31, 2004 are not necessarily indicative of the results that may be expected for the year ending December 31, 2004. For further information, refer to the financial statements and related footnotes included in the E Med Future, Inc. annual report on Form 10-KSB for the year ended December 31, 2003.
NOTE 2 SUBSEQUENT EVENTS
On April 1, 2004, the Company entered into a convertible debenture agreement with Dr. Charles O. Mbanefo. The $750,000 debenture bears interest at 7.5% payable quarterly with the principal due in five years and is secured by all of the Company’s assets. The debenture is convertible at Dr. Mbanefo’s option to 1.5 million shares of the Company’s unregistered common stock. Proceeds from the debenture will be used for inventory and operating expenses. In connection with the debenture, the Company also agreed to pay Dr. Mbanefo a $2.00 royalty on the next 1.0 million NeedleZap units sold.
Item 2. Management’s Discussion and Analysis
Headquartered in Columbus, Ohio, E Med Future, Inc. manufactures and markets products designed to reduce accidental hypodermic needlestick injuries. Our primary product, NeedleZap®, completely disintegrates the sharp portion of the needle. According to the American Nursing Association, there are an estimated one million accidental needlesticks reported in the United States in the healthcare industry alone. We believe the applications for the product are far reaching, and include healthcare professionals, law enforcement and correctional personnel, veterinarians, military, clinical researchers, hospitality, and sanitation workers. NeedleZap is designed to work within the parameters of recent OSHA needlestick mandates which require employers to take advantage of new technologies to prevent needlesticks in the workplace.
Our primary product is NeedleZap®, a revolutionary safety device intended to help reduce accidental needlestick injuries by disintegrating the sharp portion of a hypodermic needle. When a hypodermic needle is inserted into the unit, the patented electrode system disintegrates the needle in approximately two seconds at 2200° F.
6
In July 2003, we announced the beginning of clinical testing and market evaluation of the first extensions to the NeedleZap product line which include a dental parking station and butterfly needle burner. Both products are currently in development and we are presently in the process of obtaining patent protection for these new products. We anticipate that both products will involve supplements to our existing FDA pre market approval; therefore, introduction and timing of these products into the marketplace will be contingent on FDA approval.
The dental parking station is intended to provide a safer, temporary resting place for a hypodermic syringe. During a procedure, dentists often reuse a hypodermic needle on the same patient when additional anesthesia is required. Since the needle is not destroyed immediately after the initial use, dentists often recap the needle or leave the needle exposed, increasing the risk of an accidental needlestick injury. The NeedleZap unit sets directly on the dental parking station enabling the dentist to recap, or disintegrate, the hypodermic needle easily with one hand at the end of the procedure, and significantly reducing the risk of a needlestick injury.
The butterfly needle burner is intended to accommodate needles not secured to a hypodermic syringe. Butterfly needles are used primarily for IV’s and kidney dialysis. Since the original NeedleZap unit was intended to disintegrate hypodermic needles held by a syringe, the butterfly needle burner necessitated design modifications, including a change to the housing and repositioning of the electrode system.
To further expand our product offerings, we have entered into a strategic alliance agreement with UTEK Corporation (AMEX:UTK), an innovative technology transfer company dedicated to building bridges between university developed technologies and commercial organizations. UTEK will identify and evaluate new technologies developed by universities and government laboratories that would be synergistic with our existing product line for our possible acquisition.
On December 30, 2003, we acquired Medical Safety Technologies, Inc. from UTEK. Medical Safety Technologies, or MSTI, holds the worldwide exclusive license to a patented invention, known as the Safe Receptacle for Sharps, that is designed to aid in the safe transport of sterile and used sharp medical instruments. This Emory University invention was developed to help reduce the possibility of needlestick injuries by maintaining medical instruments in an angled, accessible position while encasing their sharp edges. We are enthusiastic about adding the Safe Receptacle for Sharps device to our product line and believe that it is a complimentary technology to our NeedleZap® product. By expanding our future product line, we hope to bring added value to the sales and distribution channel we are building.
On April 1, 2004, we entered into a convertible debenture agreement with Dr. Charles O. Mbanefo in the amount of $750,000. The debenture bears interest at 7.5% payable quarterly with the principal due in five years and is secured by all of our assets. The debenture is convertible at Dr. Mbanefo’s option into 1.5 million shares of our unregistered common stock. Proceeds from the debenture will be used for inventory and operating expenses. In connection with the debenture, we also agreed to pay Dr. Mbanefo a $2.00 royalty on each of the next 1.0 million NeedleZap units sold.
In May, we announced that our exclusive sales and marketing partner, American Health & Safety Products, Inc. (AHSP), secured agreements with Patterson Dental Supply, Inc. and
7
Sullivan-Schein Dental® to distribute our dental parking station to the dental community throughout the United States. Patterson Dental Supply provides a virtually complete range of consumable dental products, clinical and laboratory equipment, and value-added services to dentists, dental laboratories and institutions throughout North America. Sullivan-Schein Dental, a Henry Schein Company, offers a broad array of products and services to dental customers. The company currently serves more than 75% of the dental practices in the United States.
In May we also announced that E Med has received a registration number from the Mexican Health Department (Secretaria de Salud) to sell NeedleZap through our distribution partners in Mexico, Intrasol de Mexico, S.A. de C.V. and AHSP.
We incurred net losses in 2002 and 2003 while we obtained FDA approval for our NeedleZap product, applied for patent protection and entered into distribution relationships. We have not had significant sales volume to date, but now that we have FDA approval and established distribution channels, we are excited about the prospect for sales in the United States and abroad. There are an estimated one million accidental needlesticks reported in the United States in the healthcare industry alone, and we believe the applications for our products are far reaching. NeedleZap is designed to work within the parameters of recent OSHA needlestick mandates which require employers to take advantage of new technologies to prevent needlesticks in the workplace. We also believe there is a potential global market in developed as well as developing countries. For example, NeedleZap could be a component in the fight against AIDS in many African countries where the disease is endemic. With all regulatory matters resolved, we anticipate an increase in sales in 2004. Of course, we cannot guaranty that sales will increase or that we will be able to attain profitability.
The Company was formed under the laws of the State of Nevada on March 14, 1990, but until last year we were a shell company with no significant operations other than seeking to identify an existing business to acquire. Trading in our stock was dependant on our acquisition of an operating business. On April 4, 2003, we participated in a merger in which we acquired E Med Future, Inc., our operating subsidiary. In connection with the transaction, we issued 19,850,000 unregistered shares of our common stock (95% of our outstanding shares) to the former stockholders of E Med Future.
Pursuant to the terms of the merger agreement, we changed our corporate name from “Micro-Economics, Inc.” to “E Med Future, Inc.” In addition, our original directors resigned and were replaced by Robert J. Ochsendorf, D. Dane Donohue and Juan J. Perez. Messrs. Ochsendorf and Donohue now serve as our CEO and executive vice president, respectively. Our shares began trading on the Over-the-Counter Bulletin Board under the symbol “EMDF.OB” on April 17, 2003. For additional information about the merger, please see the Current Report on Form 8-K dated April 4, 2003 that we filed with the SEC on April 11, 2003.
In December 2001, we filed a pre-market approval application, or PMA, with The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for NeedleZap. On the basis of counsel’s advice, we determined that NeedleZap was not regulated by the CDRH as a medical device in veterinarian or law enforcement applications. Therefore, we
8
opted to market NeedleZap in the United States to veterinarians and law enforcement professionals. Revenues generated from these sales would offset the costly and lengthy FDA approval process and provide funding for promotion, tooling, parts and the overall operations.
In July 2002, we received an approvable letter from the FDA stating that NeedleZap met all the requirements for the safety and effectiveness data testing for a Class III medical device. The approvable letter was subject to an FDA inspection that found the manufacturing facilities, methods and controls in compliance with the applicable requirements of FDA quality system regulation. During the manufacturing inspectional phase in August 2002, the FDA requested that we suspend all sales to veterinarian and law enforcement markets until the product was fully approved. We voluntarily complied with the FDA’s request and suspended all sales in U.S. markets.
On March 14, 2003, the FDA issued a final approval order letter for NeedleZap. Final labeling was submitted and approved on March 19, 2003, clearing the way to market NeedleZap in the United States in healthcare facilities and treatment settings.
We are a development stage company. Because we did not have full approval to market and sell our products until March 2003, we do not believe a detailed comparison of results from the first quarter of 2004 to 2003 to be informative. For addition information regarding the history of our business, please see “Our History” above.
We had net sales of $129,026 in the quarter ended March 31, 2004, compared with $50,542 for the same period in 2003, an increase of $78,484 or 155.3%. This increase is primarily attributable to increased international sales and U.S. sales following the FDA’s approval of NeedleZap in March 2003.
Operating costs and expenses decreased $473,462, or 65.1%, to $254,161 in the first quarter of 2004 from $727,623 in 2003. The first quarter of 2003 was impacted by $600,000 in stock based compensation expenses as a result of our issuance of four million shares in April 2003 as compensation for consulting services previously rendered. This effect was partially offset by increased selling, general and administrative expense in 2004 due to higher distributor training and promotional costs. As a percentage of net sales, cost of goods sold decreased to 58.7% in 2004 from 129.2% in 2003 due to increased sales in 2004.
Other expenses increased to $1,738 in 2004 from none in 2003, due to an increase in interest expense resulting from higher balances outstanding on our interest bearing debt in 2004.
In the first quarter of 2004, our net loss decreased to $126,873, or $0.01 a share, from a net loss of $677,081 in 2003 as a result of increased sales combined with lower costs.
9
Financial Condition and Liquidity
We had available cash of $5,002, on March 31, 2004, compared to $7,964 at the end of the first quarter of 2003. Cash used in operations increased 130.1% to $138,622 in the first quarter of 2004 from $60,252 in 2003, primarily caused by an increase in accounts payable to a related party as we borrowed to fund the build-up of inventory in 2004.
On November 12, 2002, we entered into a credit facility with KeyBank (NA). The facility provides us with a working capital line-of-credit of up to $150,000 and currently bears interest at 4.5%. The credit facility is secured by all of E Med’s assets and must be paid back in full on demand. We presently have drawn $141,098 on the facility.
In 2003, our director of research purchased an existing $215,585 loan and advanced additional funds bringing total funds advanced to $320,585. In the first quarter of 2004, we repaid $53,500 of this loan, reducing the outstanding balance to $267,085. The new consolidated loan is due December 31, 2006 and bears interest at 7%.
Our primary need for capital is to fund operations and the development of new products. Historically, our capital requirements have been met by a combination of loans from stockholders, our line of credit with Key Bank, and funds from operations. In April we addressed our immediate liquidity needs by selling a $750,000 debenture. For more information about the debenture, please turn to “Recent Events” on page 7. Now that our distributors have had sufficient ramp-up time, we expect increased sales to meet our capital needs. In addition, we are developing new NeedleZap products to help generate additional revenues. However, sales may not be adequate to meet our cash needs, which would negatively impact our operations and development of new and ancillary products.
Off-Balance Sheet Arrangements
We do not have any material off-balance sheet arrangements.
Some of the statements that we make in this report, including statements about our confidence in E Med’s prospects and strategies and our expectations about E Med’s sales expansion, are forward-looking statements within the meaning of § 21E of the Securities Exchange Act. Some of these forward-looking statements can be identified by words like “believe,” “expect,” “will,” “should,” “intend,” “plan,” or similar terms; others can be determined by context. Statements contained in this report that are not historical facts are forward-looking statements. These statements are necessarily estimates reflecting our best judgment based upon current information, and involve a number of risks and uncertainties. Many factors could affect the accuracy of these forward-looking statements, causing our actual results to differ significantly from those anticipated in these statements. While it is impossible to identify all applicable risks and uncertainties, they include:
| • | our ability to execute our business plan; |
| • | our ability to successfully market and sell our products; |
| • | our ability to gain and retain market share from our competitors, many of whom have greater financial and other resources than we do; |
10
| • | the introduction of competing products by other firms; |
| • | our ability to protect our patents, copyrights and other intellectual property rights; |
| • | pressure on pricing from our competitors or customers; |
| • | continued availability of components for our products and stability in the cost of these components; |
| • | our reliance on subcontractors to manufacture our products; |
| • | our financial resources are limited and we are dependant on increasing sales to generate cash for operations; and |
| • | our ability to continue to comply with rules and regulations governing our products. |
You should not place undue reliance on our forward-looking statements, which reflect our analysis only as of the date of this report. The risks and uncertainties listed above and elsewhere in this report and other documents that we file with the Securities and Exchange Commission, including our annual report on Form 10-KSB, quarterly reports on Form 10-QSB, and any current reports on Form 8-K, must be carefully considered by any investor or potential investor in E Med.
We file annual, quarterly and special reports and other information with the SEC. Our SEC filings are available to the public over the internet at the SEC’s web site at SEC.gov. You may also read and copy any document we file at the SEC’s public reference room at 450 Fifth Street, N.W., Washington, D.C. 20549. You may obtain information on the operation of the SEC’s public reference room in Washington, D.C. by calling the SEC at 1-800-SEC-0330. To learn more about E Med you can also contact us directly at the address or phone number listed below or visit our website at NeedleZap.com.
E Med Future, Inc.
794 Morrison Road
Suite 911
Columbus, Ohio 43230
Phone: 877- 855-1319
Email: info@NeedleZap.com
Item 3. Controls and Procedures
Robert J. Ochsendorf, our President and Chief Executive Officer, and D. Dane Donohue, our Executive Vice President, have reviewed E Med’s disclosure controls and procedures as of March 31, 2004. Based upon their review, they believe that our disclosure controls and procedures are effective in ensuring that material information related to E Med is communicated to them by others within the company responsible for reporting this information.
11
Not applicable.
Item 2. Changes in Securities and Use of Proceeds
Not applicable.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Submission of Matters to a Vote of Security Holders
Not applicable.
Not applicable.
Item 6. Exhibits and Reports on Form 8-K
| (a) | Exhibits |
| 31.1 | CEO’s Rule 13a-14(a)/15d-14(a) Certification Pursuant to § 302 of the Sarbanes-Oxley Act of 2002 | |
| 31.2 | CFO’s Rule 13a-14(a)/15d-14(a) Certification Pursuant to § 302 of the Sarbanes-Oxley Act of 2002 | |
| 32 | Rule 13a-14(b)/15d-14(b) Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 | |
| (b) | Reports on Form 8-K |
On March 15, 2004, we filed a Current Report on Form 8-K dated December 30, 2003 including the audited financial statements of Medical Safety Technologies, Inc. as of December 30, 2003 and E Med’s pro forma financial information giving effect to the acquisition of Medical Safety Technologies.
12
In accordance with the requirements of the Exchange Act, E Med Future, Inc. caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| E MED FUTURE, INC. | ||||
| Date: May 14, 2004 |
By |
/s/ D. Dane Donohue | ||
| D. Dane Donohue, Executive Vice President | ||||
13